Lymphangiogenic gene therapy with minimal blood vascular side effects - sprookjes - yvandenbroek - TriplyDB

Lymphangiogenic gene therapy with minimal blood vascular side effects

Lymphangiogenic gene therapy with minimal blood vascular side effects

http://www.wikidata.org/entity/Q36371262

about

FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1 Lymphatic vessel density and function in experimental bladder cancer.Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.Lymphangiogenesis-independent resolution of experimental edema.The lymphatic system in health and disease.Cell-cell interactions influence vascular reprogramming by Prox1 during embryonic development.Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling.Vascular endothelial growth factor-C accelerates diabetic wound healing Milroy disease and the VEGFR-3 mutation phenotype.Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.Altered lymphatics in an ovine model of congenital heart disease with increased pulmonary blood flow.Lymphatic function is regulated by a coordinated expression of lymphangiogenic and anti-lymphangiogenic cytokines.Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.Lymphangiogenesis and expression of specific molecules as lymphatic endothelial cell markers.Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos Potential therapeutic strategies for lymphatic metastasis.Biomarkers of lymphatic function and disease: state of the art and future directions.VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis.Characterization of internodal collecting lymphatic vessel function after surgical removal of an axillary lymph node in mice Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues Emerging Role of Sphingosine-1-phosphate in Inflammation, Cancer, and Lymphangiogenesis.Dose-dependent response of FGF-2 for lymphangiogenesis Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.Shaping of Peripheral T Cell Responses by Lymphatic Endothelial Cells.Lymphangiogenic factors, mechanisms, and applications.Modulation of VEGF-induced migration and network formation by lymphatic endothelial cells: Roles of platelets and podoplanin.VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection.The formation of lymphatic vessels and its importance in the setting of malignancy Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites.Desmoplakin and Plakoglobin--specific markers of lymphatic vessels in the skin?Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.Lymphatic Vessels: The Next Frontier in Lung Transplant.Observation of electrostatically released DNA from gold electrodes with controlled threshold voltages.Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema.Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels.Physiological Perspective on Therapies of Lymphatic Vessels.Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease

P2860

Q24641842-9FAB99E5-15A4-4B74-8459-C565355E6C0A Q30481281-43AD79C1-8DBF-4FC4-B9D5-C095792D249A Q33731734-8E647D2E-D272-4A19-BEF9-48115F614569 Q33994917-86B6C80A-A12C-4CDF-B56D-138BB2CE183C Q34015299-5B988C74-278E-461F-AF80-33A0DD776815 Q34558235-11DCEF6B-7FCC-40BB-942D-DAE685839FD7 Q35087757-309B5C52-A303-4C34-B0DE-FCACF1AF3BE7 Q35222023-9B475A0B-378C-476B-B210-275AEA35FE24 Q35447741-0106DA46-F32E-48A7-811D-DC46EE42F923 Q35574091-53D364CF-127D-4760-98AD-F08233D090AD Q35850300-64A647C1-AE12-4E56-B374-0A2279CEC843 Q35895537-228028F8-6394-4FF4-88E9-4EBB3652DBA8 Q36229454-D010ACB4-754E-44E7-80E1-3BB17DCD791A Q36519259-D9F80501-5FF3-4B30-801E-D9445DFF21E4 Q36804671-49BB43C1-DC75-4677-93DB-FAEB1F380D47 Q36851512-40FA07C9-D860-4934-A92B-05869C9FACED Q36913026-EF319758-D4C2-461D-AD5E-67A7335AE5D4 Q37035753-1CF6BC0B-30E6-431A-8583-BEC550CEDAFD Q37057569-D798E964-23C8-4D3D-BB0D-5D381BA2310A Q37061129-088D6ADC-30CE-4A3F-8E45-5E89FF386F7B Q37341131-999A7A26-C880-45F3-ADB7-691CE564377A Q37415307-21857226-DFB0-48F6-A982-1844FE7C3A22 Q37551405-60E843D0-6CED-491D-900A-26C3406ADC0A Q37580778-36D58925-53DD-48B3-84B6-7C1117353192 Q38192927-0FDDF957-26A7-4649-A3B8-23576298D205 Q38670274-036E4366-24E1-4C22-A21B-C38981A3FBD3 Q39001886-E9D47710-00E9-496D-BA9E-23A4557DFC9F Q40410213-3E75952F-6C3A-4303-BD72-2E19A769ECA8 Q42025717-E53DBA01-E9B3-4C4D-89DC-7895B9310A04 Q44526093-91609CF4-2B82-4C15-9C3C-FE7ABEFD6AAA Q47602995-B434EC7B-6D48-4962-AD36-294A22722984 Q48542106-A61C1861-7B47-4D9D-9F1B-7B048C181C2E Q49847182-511DCA27-3D05-46A7-936A-BE18707281C3 Q51642955-A245E9D2-BCE2-4ABB-97C7-515381B7B395 Q54372705-92FF05CB-13B9-4D8D-B706-F8A57BEDD547 Q54985404-0A07E13B-8FC6-4842-8813-88BFD0148999 Q55426074-762D8745-5AC1-4315-898F-B709693DAAF2 Q56336013-54B1AA28-8010-4D90-B942-8B2DA788AA99

P2860

Lymphangiogenic gene therapy with minimal blood vascular side effects

http://www.wikidata.org/entity/Q36371262

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Lymphangiogenic gene therapy with minimal blood vascular side effects

@ast

Lymphangiogenic gene therapy with minimal blood vascular side effects

@en

type

label

Lymphangiogenic gene therapy with minimal blood vascular side effects

@ast

Lymphangiogenic gene therapy with minimal blood vascular side effects

@en

prefLabel

Lymphangiogenic gene therapy with minimal blood vascular side effects

@ast

Lymphangiogenic gene therapy with minimal blood vascular side effects

@en

P1433

Q36371262-F977F699-92F2-45AA-8755-D1F39759D7C3

P1476

Q36371262-6F96695F-C231-44C7-AB68-57C3F5A93090

P2093

Q36371262-0A055541-8739-4C65-A4D8-073565316A4C

Q36371262-25BD54BB-50B5-41F5-A3ED-64CB84253E9B

Q36371262-2611A90B-4900-45B3-92FB-8D667DD414D1

Q36371262-84681BB7-35E6-4E84-800A-17BB0B48EDA8

Q36371262-862C34C8-7E97-4D6F-944B-A70700D7CD2F

Q36371262-89CB5BF8-5F89-4C73-83AA-863B0C700F5A

P2860

Q36371262-0628B404-1043-419A-822F-F557DB0A4B67

Q36371262-125A6067-4523-430E-8B41-0C4FE2C45F25

Q36371262-1A0DA101-A470-47E7-9694-7D7985AAD3BF

Q36371262-273C5C85-99A6-4537-A082-CB09047FF582

Q36371262-2F5539EA-34E2-43DA-BDAC-DEF5D735EE09

Q36371262-3A79887F-D19C-46F8-A60B-F168C1D177F8

Q36371262-3B2349B4-6A6B-4C15-B293-36EEE93046EC

Q36371262-3C701FE8-ABB9-4396-BEC7-1DA0D64D08A0

Q36371262-3D5EBDA9-72B8-441D-AD0C-9EFB42A94052

Q36371262-41B8AF40-F4F6-43AC-B907-BBDA90B3B760

P304

Q36371262-E9638603-3A47-4FB9-9867-8DE4ADBD2A8C

P31

Q36371262-BE473D94-D7C8-490A-A393-4463942CB0D9

P356

Q36371262-826060FD-10D6-4120-B76C-71D3811D1D14

P407

Q36371262-D0B7B7D5-40A4-4153-95DB-6A56F47207CD

P433

Q36371262-92D22BE3-5D6D-4D69-8B24-4AC3CD7C7DD1

P478

Q36371262-AE6F5688-F872-437B-9710-5C2D85202573

P50

Q36371262-5F1F1195-C227-4983-A075-7E9127945F53

Q36371262-891DD2E0-143B-4455-B9A6-BAAD2605CA1E

Q36371262-8D48E1C1-F0BF-4448-A082-4DE29A4B3111

P577

Q36371262-0F19BEBF-94DD-4ADD-9C78-F2623F832F2B

P5875

Q36371262-99414294-0907-469C-AD90-62D8694CD5C5

P698

Q36371262-DE575263-3047-44D0-8CA7-E4365936E764

P921

Q36371262-5B10F30C-4862-4FF1-B517-1B24ABC83792

P932

Q36371262-002F57D9-71D8-4EEB-89F7-CE9E51B9BE77

P356

P1433

Journal of Experimental Medicine

P1476

Lymphangiogenic gene therapy with minimal blood vascular side effects

@en

P2093

Anne Saaristo

http://www.w3.org/2001/XMLSchema#string

Berndt Enholm

http://www.w3.org/2001/XMLSchema#string

Hansruedi Bueler

http://www.w3.org/2001/XMLSchema#string

Katri Pajusola

http://www.w3.org/2001/XMLSchema#string

Marika J Karkkainen

http://www.w3.org/2001/XMLSchema#string

Tanja Veikkola

http://www.w3.org/2001/XMLSchema#string

P2860

Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

A model for gene therapy of human hereditary lymphedema

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.

Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane

Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1

P304

719-730

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20020587

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

196

http://www.w3.org/2001/XMLSchema#string

P50

Seppo Ylä-Herttuala

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11155889

http://www.w3.org/2001/XMLSchema#string

P698

12235206

http://www.w3.org/2001/XMLSchema#string

P921

P932

2194057

http://www.w3.org/2001/XMLSchema#string